Title: USE OF NON-ANTIBACTERIAL TETRACYCLINE ANALOGS AND FORMULATIONS THEREOF FOR THE TREATMENT OF BACTERIAL EXOTOXINS

Abstract: The invention relates to methods for protecting and/or treating a mammal at risk of acquiring a condition associated with bacteria that produce a calmodulin exotoxin, a metalloproteinase exotoxin, or both, by administering a non-antibacterial tetracycline formulation.
TITLE: USE OF NON-ANTIBACTERIAL TETRACYCLINE ANALOGS AND FORMULATIONS THEREOF FOR THE TREATMENT OF BACTERIAL EXOTOXINS

BACKGROUND OF THE INVENTION

When bacteria attack a host, there is an incubation period during which there are mild or no symptoms. The incubation period varies among bacteria.

Once inside the host, some bacteria begin producing exotoxins. These exotoxins damage host tissue and organs, sometimes causing a sudden onset of hyperacute illness which progresses to shock, coma and death.

For example, an inhalation infection with Bacillus anthracis (anthrax) can have an incubation period of 3 to 60 days. Death from anthrax inhalation is considered inevitable if untreated, and probable in as many as 95% of treated cases if therapy is begun more than 48 hours after the onset of symptoms.

The lack of warning symptoms, sudden onset and almost absolute mortality, among other factors, have made anthrax a choice disease for use as a biological weapon of mass destruction. The threat of such a weapon has heightened research into modes of treatment and prevention of anthrax.

Of particular interest is a treatment for individuals at high risk of exposure, as well as for those who may have been exposed to anthrax, but are without symptoms. Currently, antibiotics such as ciprofloxacin are prescribed for such individuals. Due to the variably long incubation period with the inhaled form of anthrax, individuals potentially exposed are often put on an antibiotic therapy for sixty days.

Antibiotics target the bacteria itself. Often, in bacterial infections such as anthrax, the conventional therapy of antibiotics is administered too late. For example, ciprofloxacin has substantially no effect on the exotoxins released by the bacteria, which is the eventual cause of death. Therefore, once the infection has progressed to the point where sufficient exotoxin has been released, antibiotics alone have little or
no effect. Even if the bacteria have been eliminated, remaining exotoxins may continue to cause tissue damage leading to death.

The problem with prescribing antibiotics as a treatment for individuals who may or may not be infected with bacteria such as anthrax is antibiotic resistance. The Center for Disease Control (CDC) has called antibiotic resistance one of the world’s most pressing health problems. See, www.cdc.gov/antibioticresistance/. Thus, prescribing a sixty day course of antibiotics to potentially anthrax-exposed individuals increases the likelihood of antibiotic-resistant bacterial strains.

Hence, the prior art treatments for exotoxin-releasing bacterial infections, such as anthrax, are disadvantageous. Current treatments, such as administration of ciprofloxacin, do not target the deadly exotoxins or protect against tissue and organ damage. Moreover, a potentially unnecessary sixty day course of antibiotics may lead to antibiotic resistant bacterial strains.

An ideal treatment for exotoxin-releasing bacteria would be the targeting and neutralization, or disabling of the deadly exotoxins. Such treatment would provide protection against the exotoxins without using antibiotics until actual bacterial infection has been confirmed.

The compound, tetracycline is a member of a class of antibiotic compounds that is referred to as the tetracyclines, tetracycline compounds, tetracycline derivatives and the like. The compound tetracycline exhibits the following general structure:
The numbering system of the tetracycline ring nucleus is as follows:

![Structure B](image)

**Structure B**

Tetracycline, as well as the terramycin and aureomycin derivatives, exist in nature, and are well known antibiotics. Natural tetracyclines may be modified without losing their antibiotic properties, although certain elements must be retained. The modifications that may and may not be made to the basic tetracycline structure have been reviewed by Mitscher in *The Chemistry of Tetracyclines*, Chapter 6, Marcel Dekker, Publishers, New York (1978). According to Mitscher, the substituents at positions 5-9 of the tetracycline ring system may be modified without the complete loss of antibiotic properties.

Changes to the basic ring system or replacement of the substituents at positions 4 and 10-12, however, generally lead to synthetic tetracyclines with substantially less or effectively no antimicrobial activity. Some examples of chemically modified non-antibacterial tetracyclines (hereinafter CMTs) are 4-dedimethylaminotetracycline, 4-dedimethylaminosancycline (6-demethyl-6-deoxy-4-dedimethylaminotetracycline), 4-dedimethylaminominocycline (7-dimethylamino-6-demethyl-6-deoxy-4-dedimethylaminotetracycline), and 4-dedimethylaminodoxycycline (5-hydroxy-6-deoxy-4-dedimethylaminotetracycline).

In addition to their antimicrobial properties, tetracyclines have been described as having a number of other uses. For example, tetracyclines are also known to inhibit the activity of collagen destructive enzymes produced by mammalian (including human) cells and tissues by non-antibiotic mechanisms. Such enzymes include the matrix metalloproteinases (MMPs), including collagenases (MMP-1, MMP-8 and MMP-13), gelatinases (MMP-2 and MMP-9), and others (e.g. MMP-12, MMP-14). See Golub et al., *J. Periodont. Res.* 20:12-23 (1985); Golub et al. *Crit. Revs. Oral Biol. Med.* 2:297-322 (1991); U.S. Patent Nos. 4,666,897; 4,704,383;
4,935,411; 4,9354,412. Also, tetracyclines have been known to inhibit wasting and protein degradation in mammalian skeletal muscle, U.S. Pat. No. 5,045,538, to inhibit inducible NO synthase, U.S. Patent Nos. 6,043,231 and 5,523,297, and phospholipase A2, U.S. Patent Nos. 5,789,395 and 5,919,775, and to enhance IL-10 production in mammalian cells. These properties cause the tetracyclines to be useful in treating a number of diseases.

The object of this invention is to provide a method for protecting a mammal infected by, or at risk of exposure to, bacteria that produce exotoxins such as anthrax without the risk of antibiotic resistance.

**SUMMARY OF THE INVENTION**

It has now been discovered that these and other objectives can be achieved by the following methods.

In a first embodiment of the invention, a method for protecting a mammal at risk of acquiring a condition associated with bacteria that produce a calmodulin exotoxin, a metalloproteinate exotoxin, or both, is provided.

In a second embodiment, a method for treating a mammal having a condition associated with bacteria that produce a calmodulin exotoxin, a metalloproteinate exotoxin, or both, is provided.

In a third embodiment, a method for protecting a mammal that has received or is scheduled to receive a vaccine against a bacteria that produces a calmodulin exotoxin, metalloproteinate exotoxin, or both, is provided.

In a fourth embodiment, the bacteria can be selected from the group consisting of *Bacillus anthracis*, *Clostridium perfringens*, *Bordetella pertussis*, *Bacteroides fragilis*, or *Pseudomonas aeruginosa*.

In one embodiment, the methods comprise administering to the mammal an effective amount of a non-antibacterial tetracycline, or a pharmaceutically acceptable salt thereof.
In another embodiment, the method comprises administering to the mammal an effective, non-antibacterial amount of an antibacterial tetracycline, or a pharmaceutically acceptable salt thereof.

In another embodiment, the method further includes administration of an antibiotic, along with the non-antibacterial or non-antibacterial amount of the tetracycline.

In an additional embodiment the tetracycline is administered before a vaccine is administered, at the same time that a vaccine is administered, or after a vaccine is administered.

**DETAILED DESCRIPTION**

The invention relates to treating conditions associated with a bacterial exotoxin with a tetracycline derivative. Tetracycline derivatives, for purposes of the invention, may be any tetracycline derivative.

In one embodiment of the invention, antibacterial tetracycline compounds are administered in a non-antibacterial amount. For this embodiment, the tetracycline derivative may be any such derivative having clinically significant antibacterial activity. Some examples of antibacterial tetracycline derivatives include tetracycline, as well as the 5-OH (oxytetracycline, e.g., terramycin™) and 7-Cl (chlorotetracycline, e.g., aureomycin™) derivatives, which exist in nature, are employed. Semisynthetic tetracyclines, which include, for example, doxycycline, minocycline and sancycline, can also be used for this embodiment.

The amount of a tetracycline compound that has substantially no antibacterial activity is an amount that does not significantly prevent the growth of bacteria. For example, tetracycline compounds that have significant antibacterial activity may be administered in an amount which is 10-80% of the antibacterial amount. More preferably, the antibacterial tetracycline compound is administered in an amount which is 40-70% of the antibacterial amount.
Some examples of antibacterial amounts of members of the tetracycline family include 100mg/day of doxycycline, 200mg/day of minocycline, 250mg of tetracycline four times a day, 1000mg/day of oxytetracycline, 600mg/day of demeclocycline and 600mg/day of lymecycline.

Examples of antibacterial tetracyclines administered in a non-antibacterial amount are depicted in Table 1, as follows:

<table>
<thead>
<tr>
<th>Drug</th>
<th>Maximum Non-Antimicrobial Dose</th>
<th>Plasma Antimicrobial Threshold Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>Doxycycline</td>
<td>20 mg b.i.d</td>
<td>1.0 mcg/mL</td>
</tr>
<tr>
<td>Minocycline</td>
<td>38 mg q.d.</td>
<td>0.8 mcg/mL</td>
</tr>
<tr>
<td>Tetracycline</td>
<td>60 mg q.d.</td>
<td>0.5 mcg/mL</td>
</tr>
</tbody>
</table>

Doxycycline administered at a 20 milligram dose twice daily is sold for the treatment of periodontal disease by CollaGenex Pharmaceuticals, Inc. of Newtown, Pennsylvania under the trademark Periostat®.

In another embodiment of the invention, non-antibacterial tetracycline compounds are administered. For this embodiment, a class of compounds has been defined which are structurally related to the antibiotic tetracyclines, but which have had their antibiotic activity substantially or completely eliminated by chemical modification. Substantial elimination of antibiotic activity occurs when the antibiotic activity is ten times less than that of tetracycline, and preferably five times less than that of doxycycline.

One such group of chemically modified nonantibacterial tetracyclines (CMT’s) includes any of the antibacterial 4-dedimethylaminotetracycline derivatives. Some examples of non-antibacterial tetracyclines include those compounds disclosed generically or specifically in co-pending U.S. patent application serial no. 09/573,654 filed on May 18, 2000, which are herein incorporated by reference.
Some examples of suitable 4-dedimethylaminotetracycline derivatives include the following general formulae (I) through (IV):

**General Formula (I)**

Structure A represents the 4-dedimethylaminosancycline (CMT-3) derivatives

![Structure A](image)

wherein R7, R8, and R9 taken together in each case, have the following meanings:

<table>
<thead>
<tr>
<th></th>
<th>R7</th>
<th>R8</th>
<th>R9</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>azido</td>
<td>hydrogen</td>
<td>hydrogen</td>
</tr>
<tr>
<td></td>
<td>dimethylamino</td>
<td>hydrogen</td>
<td>azido</td>
</tr>
<tr>
<td></td>
<td>hydrogen</td>
<td>hydrogen</td>
<td>azido</td>
</tr>
<tr>
<td></td>
<td>dimethylamino</td>
<td>hydrogen</td>
<td>amino</td>
</tr>
<tr>
<td></td>
<td>acylamino</td>
<td>hydrogen</td>
<td>hydrogen</td>
</tr>
<tr>
<td></td>
<td>amino</td>
<td>hydrogen</td>
<td>nitro</td>
</tr>
<tr>
<td>15</td>
<td>hydrogen</td>
<td>hydrogen</td>
<td>(N,N-dimethyl)glycylamino</td>
</tr>
<tr>
<td></td>
<td>amino</td>
<td>hydrogen</td>
<td>amino</td>
</tr>
<tr>
<td></td>
<td>hydrogen</td>
<td>hydrogen</td>
<td>ethoxythiocarbonylthio</td>
</tr>
<tr>
<td></td>
<td>dimethylamino</td>
<td>hydrogen</td>
<td>acylamino</td>
</tr>
<tr>
<td></td>
<td>dimethylamino</td>
<td>hydrogen</td>
<td>diazonium</td>
</tr>
<tr>
<td>20</td>
<td>dimethylamino</td>
<td>chloro</td>
<td>aminio</td>
</tr>
<tr>
<td></td>
<td>hydrogen</td>
<td>chloro</td>
<td>aminio</td>
</tr>
<tr>
<td></td>
<td>amino</td>
<td>chloro</td>
<td>aminio</td>
</tr>
<tr>
<td></td>
<td>acylamino</td>
<td>chloro</td>
<td>acylamino</td>
</tr>
</tbody>
</table>
amino  chloro  hydrogen  
acylamino  chloro  hydrogen  
monoalkylamino  chloro  amino  
nitro  chloro  amino  
5  dimethylamino  chloro  acylamino  
dimethylamino  chloro  dimethylamino  
acylamino  hydrogen  hydrogen  
hydrogen  hydrogen  acylamino  
(CMT-301)  bromo  hydrogen  hydrogen  
10  (CMT-302)  nitro  hydrogen  hydrogen  
(CMT-303)  hydrogen  hydrogen  nitro  
(CMT-304)  acetamido  hydrogen  hydrogen  
(CMT-305)  hydrogen  hydrogen  acetamido  
(CMT-306)  hydrogen  hydrogen  dimethylamino  
15  (CMT-307)  amino  hydrogen  hydrogen  
(CMT-308)  hydrogen  hydrogen  amino  
(CMT-309)  hydrogen  hydrogen  dimethylaminoacetamido  
(CMT-310)  dimethylamino  hydrogen  hydrogen  
(CMT-311)  hydrogen  hydrogen  palmitamido  
20  
R7  R8  R9  R2  

(CMT-312)  hydrogen  hydrogen  hydrogen  CONHCH2-pyrrolidin-1-yl  
(CMT-313)  hydrogen  hydrogen  hydrogen  CONHCH2-piperadlin-1-yl  
25  (CMT-314)  hydrogen  hydrogen  hydrogen  CONHCH2-morpholin-1-yl  
(CMT-315)  hydrogen  hydrogen  hydrogen  CONHCH2-piperazin-1-yl  

**General Formula (II)**

Structures B through E represent the 4-dimethylaminodoxycycline (CMT-8) derivatives
wherein R7, R8, and R9 taken together in each case, have the following meanings:

<table>
<thead>
<tr>
<th>R7</th>
<th>R8</th>
<th>R9</th>
</tr>
</thead>
<tbody>
<tr>
<td>azido</td>
<td>hydrogen</td>
<td>hydrogen</td>
</tr>
<tr>
<td>dimethylamino</td>
<td>hydrogen</td>
<td>azido</td>
</tr>
<tr>
<td>hydrogen</td>
<td>hydrogen</td>
<td>azido</td>
</tr>
<tr>
<td>dimethylamino</td>
<td>hydrogen</td>
<td>amino</td>
</tr>
</tbody>
</table>
acylamino hydrogen hydrogen
hydrogen hydrogen acylamino
amino hydrogen nitro
hydrogen hydrogen (N,N-dimethyl)glycylamino
 5 amino hydrogen amino
hydrogen hydrogen ethoxythiocarbonylthio
dimethylamino hydrogen acylamino
hydrogen hydrogen diazonium
diazonium hydrogen hydrogen
10 ethoxythiocarbonylthio hydrogen hydrogen
dimethylamino chloro amino
amino chloro amino
acylamino chloro acylamino
hydrogen chloro amino
15 amino chloro hydrogen
acylamino chloro hydrogen
monoalkylamino chloro amino
nitro chloro amino
(CMT-801) hydrogen hydrogen acetamido
(CMT-802) hydrogen hydrogen dimethylaminocetamido
(CMT-803) hydrogen hydrogen palmitamidine
(CMT-804) hydrogen hydrogen nitro
(CMT-805) hydrogen hydrogen amino
(CMT-806) hydrogen hydrogen dimethylamino
25

<table>
<thead>
<tr>
<th>R7</th>
<th>R8</th>
<th>R9</th>
<th>R2</th>
</tr>
</thead>
<tbody>
<tr>
<td>(CMT-807) hydrogen hydrogen hydrogen CONHCH₂-pyrrolidin-1-yl</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(CMT-808) hydrogen hydrogen hydrogen CONHCH₂-piperadin-1-yl</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(CMT-809) hydrogen hydrogen hydrogen CONHCH₂-piperazine-1-yl</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
30

**General Formula (III)**

Structure F represents the 4-dedimethylaminominocycline (CMT-10) derivatives
wherein R8 is hydrogen or halogen and R9 is selected from the group consisting of nitro (CMT-1002), (N,N-dimethyl)glycylamino, ethoxythiocarbonylthio. A compound related to structure F has a 7-trimethylammonium group instead of the 7-diemethylamino group, i.e. 7-trimethylammoniumsancycline (CMT-1001), and

General Formula (IV)
wherein R7, R8, and R9 taken together in each case, have the following meanings:

<table>
<thead>
<tr>
<th>R7</th>
<th>R8</th>
<th>R9</th>
</tr>
</thead>
<tbody>
<tr>
<td>amino</td>
<td>hydrogen</td>
<td>hydrogen</td>
</tr>
<tr>
<td>5</td>
<td>nitro</td>
<td>hydrogen</td>
</tr>
<tr>
<td>azido</td>
<td>hydrogen</td>
<td>hydrogen</td>
</tr>
<tr>
<td>dimethylamo</td>
<td>nitrogen</td>
<td>azido</td>
</tr>
<tr>
<td>hydrogen</td>
<td>hydrogen</td>
<td>amino</td>
</tr>
<tr>
<td>hydrogen</td>
<td>hydrogen</td>
<td>azido</td>
</tr>
<tr>
<td>10</td>
<td>hydrogen</td>
<td>nitro</td>
</tr>
<tr>
<td>bromo</td>
<td>hydrogen</td>
<td>hydrogen</td>
</tr>
<tr>
<td>dimethylamo</td>
<td>hydrogen</td>
<td>amino</td>
</tr>
<tr>
<td>acylamo</td>
<td>hydrogen</td>
<td>hydrogen</td>
</tr>
<tr>
<td>hydrogen</td>
<td>hydrogen</td>
<td>acylamo</td>
</tr>
<tr>
<td>15</td>
<td>amino</td>
<td>nitro</td>
</tr>
<tr>
<td>hydrogen</td>
<td>hydrogen</td>
<td>(N,N-dimethyl)glycylamo</td>
</tr>
<tr>
<td>amino</td>
<td>hydrogen</td>
<td>amino</td>
</tr>
<tr>
<td>diethylamo</td>
<td>hydrogen</td>
<td>hydrogen</td>
</tr>
<tr>
<td>hydrogen</td>
<td>hydrogen</td>
<td>ethoxythiocarbonylthio</td>
</tr>
<tr>
<td>20</td>
<td>dimethylamo</td>
<td>hydrogen</td>
</tr>
<tr>
<td>dimethylamo</td>
<td>hydrogen</td>
<td>acylamo</td>
</tr>
<tr>
<td>dimethylamo</td>
<td>chloro</td>
<td>amino</td>
</tr>
<tr>
<td>amino</td>
<td>chloro</td>
<td>amino</td>
</tr>
<tr>
<td>acylamo</td>
<td>chloro</td>
<td>acylamo</td>
</tr>
<tr>
<td>25</td>
<td>hydrogen</td>
<td>chloro</td>
</tr>
<tr>
<td>amino</td>
<td>chloro</td>
<td>amino</td>
</tr>
<tr>
<td>acylamo</td>
<td>chloro</td>
<td>hydrogen</td>
</tr>
<tr>
<td>monoalkylamo</td>
<td>chloro</td>
<td>amino</td>
</tr>
<tr>
<td>nitro</td>
<td>chloro</td>
<td>amino</td>
</tr>
<tr>
<td>30</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Additional CMT’s for purposes of the invention include, 4-de(dimethylaminotetracycline (CMT-1), include tetracycline nitrile (CMT-2), 4-
dedimethylaminochlorotetracycline (CMT-4), 4-dedimethylamino-4-
hydroxytetracycline (CMT-6), 2a-dehydroxy-4-dedimethylaminotetracycline (CMT-
7), and 1-deoxy-12a-dehydroxy-4-dedimethylaminotetracycline (CMT-9).

Non-antibacterial tetracycline compounds can be used in higher amounts than
antibacterial tetracyclines, while avoiding the indiscriminate killing of bacteria, and
the emergence of resistant bacteria. For example, 6-demethyl-6-deoxy-
4-dedimethylaminotetracycline (CMT-3) may be administered in doses of about 10 to
about 20mg/day which produces serum levels in humans of about 1µg/ml, or 40 to
about 200mg/day, or in amounts that result in serum levels in humans of about
1.55µg/ml to about 10µg/ml.

The chemically modified tetracyclines can be made by methods known in the
art. See, for example, Mitscher, L.A., The Chemistry of the Tetracycline Antibiotics,
Marcel Dekker, New York (1978), Ch. 6, and U.S. Patents 4,704,383 and 5,532,227.

The invention also includes pharmaceutically acceptable salts of the above
disclosed compounds. The present invention embraces salts, including acid-addition
and metal salts, of the 4-dedimethylaminotetracycline compounds described herein.
Such salts are formed by well known procedures. By “pharmaceutically acceptable”
is meant those salt-forming acids and metals which do not substantially contribute to
the toxicity of the compound.

Some examples of suitable salts include salts of mineral acids such as
hydrochloric, hydriodic, hydrobromic, phosphoric, metaphosphoric, nitric and sulfuric
acids, as well as salts of organic acids such as tartaric, acetic, citric, malic, benzoic,
glycollic, gluconic, gulonic, succinic, arylsulfonic, e.g. p-toluenesulfonic acids, and
the like.

After preparation, the novel compounds of the present invention can be
conveniently purified by standard methods known in the art. Some suitable examples
include crystallization from a suitable solvent or partition-column chromatography.

The preferred pharmaceutical composition for use in the method of the
invention includes a combination of the tetracycline compound in a suitable
pharmaceutical carrier (vehicle) or excipient as understood by practitioners in the art. Examples of carriers and excipients include starch, milk, sugar, certain types of clay, gelatin, stearic acid or salts thereof, magnesium or calcium stearate, talc, vegetable fats or oils, gums and glycols.

The tetracycline compound may be administered to mammals by sustained release, as is known in the art. Sustained release administration is a method of drug delivery to achieve a certain level of the drug over a particular period of time. The level typically is measured by serum concentration.

The tetracycline compounds of the invention may be administered systemically. Systemic administration can be enteral or parenteral. Enteral administration is a preferred route of delivery of the tetracycline, and compositions including the tetracycline compound with appropriate diluents, carriers, and the like are readily formulated. Liquid or solid (e.g., tablets, gelatin capsules) formulations can be employed.

Administration can also be accomplished by a nebulizer or liquid mist. Nebulization is a preferred route of delivery of the tetracycline in situations where the respiratory system is particularly infected, for example, in the case of inhalation anthrax. By utilizing a nebulizer, the tetracycline is taken directly into the individuals respiratory system through inspiration.

Parenteral administration of the tetracycline compounds of the invention (e.g., intravenous, intramuscular, subcutaneous injection) is also contemplated. Formulations using conventional diluents, carriers, etc. such as are known in the art can be employed to deliver the compound.

Alternatively, delivery of the tetracycline compounds includes topical application. Topical administration is suitable in cutaneous infections such as, for example, cutaneous anthrax. Compositions deemed to be suited for such topical use include gels, salves, lotions, ointments and the like. Controlled release delivery of topical tetracyclines can be employed such as those currently used in dentistry such as ATRIDOX® (controlled release of topical doxycycline) and ARESTIN® (controlled release of topical minocycline).
The amount of tetracycline compound administered is any amount effective for reducing or inhibiting conditions associated with a bacterial exotoxin in the infected mammal. The actual preferred amounts of tetracycline compound in a specified case will vary according to the particular compositions formulated, the mode of application, and the particular subject being treated. The appropriate dose of the tetracycline compound can readily be determined by those skilled on the art.

The minimal amount of the tetracycline compound administered to a human is the lowest amount capable of providing effective treatment of the conditions. Effective treatment is a reduction or inhibition of the conditions, a reduction or inhibition of tissue destruction and/or prevention of death, of the mammal.

The maximal amount for a mammal is the highest amount that does not cause undesirable or intolerable side effects. Such doses can be readily determined by those skilled in the art. For example, CMTs can be systemically administered in a mammal in an amount of from about 0.05mg/kg/day to about 60mg/kg/day, and preferably from about 0.3mg/kg/day to about 18mg/kg/day. The practitioner is guided by skill and knowledge in the field, and the present invention includes, without limitation, dosages that are effective to achieve the desired antibacterial activity.

The appropriate dose of the tetracycline compound for topical administration can also be readily determined by those skilled in the art. For example, topical administration of CMTs in amounts of up to about 25% (w/w) in a vehicle can be administered without any toxicity in a human. Amounts from about 0.1% to about 10% are preferred.

The tetracyclines of the present invention protect mammals at risk of acquiring a condition associated with the bacterial exotoxins calmodulin and/or metalloproteinase. Calmodulin exotoxin, otherwise known as adenylate cyclase toxin, catalyzes the conversion of ATP to cAMP. One example of a calmodulin exotoxin is the edema factor (EF) of anthrax (caused by Bacillus anthracis).

Metalloproteinase exotoxin is a peptide hydrolase which uses a metal, such as zinc, in the catalytic mechanism. For example, the lethal factor (LF) of anthrax is a zinc metalloproteinase exotoxin.
Many bacteria produce such exotoxins as part of their life cycle. For example, *Clostridium perfringens*, *Bordetella pertussis*, *Bacteriodes fragilis* and *Pseudomonas aeruginosa* are bacteria other than *Bacillus anthracis* that produce exotoxins.

A mammal which can benefit from the methods of the present invention could be any mammal. Categories of mammals include, for example, humans, farm animals, domestic animals, laboratory animals, etc. Some examples of farm animals include cows, pigs, horses, goats, etc. Some examples of domestic animals include dogs, cats, etc. Some examples of laboratory animals include rats, mice, rabbits, guinea pigs, etc.

A mammal at risk of acquiring a condition associated with a bacteria that produces a calmodulin exotoxin or a metalloproteinase exotoxin, or both, includes mammals that have been, are suspected of having been, or are expected to be exposed to, or infected with, a bacteria that produces such exotoxins. Mammals that may have been exposed to a bacteria that produces a calmodulin exotoxin or a metalloproteinase exotoxin, or both, include, for example, military personnel, individuals that handle animal skins, individuals that live in endemic areas, health care professionals who may treat or have treated infected individuals, and individuals that have been in contact with, or in the vicinity of, an area that has tested positive for the presence of such bacteria.

The methods of the invention can also include administration of an antibiotic, such as ciprofloxacin or doxycycline, to an individual having a condition associated with bacteria that produce a calmodulin exotoxin, a metalloproteinase exotoxin, or both, along with the tetracycline. The antibiotic can be administered before, concurrently, or after the tetracycline is administered.

In one embodiment, the mammal may have received, or may be scheduled to receive, a vaccine against a bacteria that produces a calmodulin or metalloproteinase exotoxin, or both. The tetracyclines of the present invention can be administered before, during or after a vaccine against a bacteria that produces a calmodulin or metalloproteinase exotoxin, or both is administered.
The tetracyclines of the present invention provide a host with protection against conditions associated with the metalloproteinase and/or calmodulin bacterial exotoxins. Conditions associated with these bacterial exotoxins include, but are not limited to, the reactions that occur once a bacterium enters the host.

Examples of such conditions include hemolysis, inhibition of protein synthesis, flaccid paralysis, spastic paralysis, emesis, inflammation, fever, shock, localized erythematous reactions, tissue destruction, diarrhea and other conditions as are known in the art, including death.
Claims:

1. A method for protecting a mammal at risk of acquiring a condition associated with bacteria that produce a calmodulin exotoxin, a metalloproteinase exotoxin, or both, the method comprising administering to the mammal an effective amount of a non-antibacterial tetracycline, or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 wherein the bacteria is selected from the group consisting of Bacillus anthracis, Clostridium perfringens, Bordetella pertussis, Bacteroides fragilis, or Pseudomonas aeruginosa.

3. The method of claim 1 wherein the bacteria is Bacillus anthracis.

4. The method of claim 1 wherein the bacteria produces a calmodulin exotoxin.

5. The method of claim 1 wherein the bacteria produces a metalloproteinase exotoxin.

6. The method of claim 1 wherein the bacteria produces both a calmodulin exotoxin and a metalloproteinase exotoxin.

7. The method of claim 1 wherein the tetracycline is selected from the group consisting of CMT-1, CMT-2, CMT-4, CMT-6, CMT-7 or CMT-9, or pharmaceutically acceptable salts thereof.

8. The method of claim 1 wherein the tetracycline is selected from the group consisting of CMT-3, or its analogs, or pharmaceutically acceptable salts thereof.

9. The method according to claim 1 wherein the tetracycline is selected from the group consisting of CMT-8, or its analogs, or pharmaceutically acceptable salts thereof.
10. The method according to claim 1 wherein the tetracycline is selected from the group consisting of CMT-10, or its analogs, or pharmaceutically acceptable salts thereof.

11. A method for treating a mammal having a condition associated with bacteria that produce a calmodulin exotoxin, a metalloproteinase exotoxin, or both, the method comprising administering to the mammal an effective amount of a non-antibacterial tetracycline, or a pharmaceutically acceptable salt thereof.

12. The method of claim 11 wherein the bacteria is selected from the group consisting of Bacillus anthracis, Clostridium perfringens, Bordetella pertussis, Bacteroides fragilis, or Pseudomonas aeruginosa.

13. The method of claim 11 wherein the bacteria is Bacillus anthracis.

14. The method of claim 11 wherein the bacteria produces a calmodulin exotoxin.

15. The method of claim 11 wherein the bacteria produces a metalloproteinase exotoxin.

16. The method of claim 11 wherein the bacteria produces both a calmodulin exotoxin and a metalloproteinase exotoxin.

17. The method of claim 11 wherein the tetracycline is selected from the group consisting of CMT-1, CMT-2, CMT-4, CMT-6, CMT-7 or CMT-9, or pharmaceutically acceptable salts thereof.

18. The method of claim 11 wherein the tetracycline is selected from the group consisting of CMT-3, or its analogs, or pharmaceutically acceptable salts thereof.

19. The method according to claim 11 wherein the tetracycline is selected from the group consisting of CMT-8, or its analogs, or pharmaceutically acceptable salts thereof.
20. The method according to claim 11 wherein the tetracycline is selected from the group consisting of CMT-10, or its analogs, or pharmaceutically acceptable salts thereof.

21. The method according to claim 11, further comprising an administering an antibiotic.

22. The method according to claim 21, wherein the antibiotic is ciprofloxacin.

23. The method according to claim 21, wherein the antibiotic is doxycycline.

24. A method for protecting a mammal at risk of acquiring a condition associated with bacteria that produce a calmodulin or a metalloprotease exotoxin, or both, the method comprising administering to the mammal an effective, non-antibacterial amount of an antibacterial tetracycline, or a pharmaceutically acceptable salt thereof.

25. The method of claim 24, wherein the bacteria is selected from the group consisting of Bacillus anthracis, Clostridium perfringens, Bordetella pertussis, Bacteroides fragilis, or Pseudomonas aeruginosa.

26. The method of claim 24, wherein the bacteria is Bacillus anthracis.

27. The method of claim 24, wherein the bacteria produces a calmodulin exotoxin.

28. The method of claim 24, wherein the bacteria produces a metalloprotease exotoxin.

29. The method of claim 24, wherein the bacteria produces both a calmodulin exotoxin and a metalloprotease exotoxin.

30. The method according to claim 24, wherein the tetracycline is selected from the group consisting of terramycin, aureomycin, doxycycline, minocycline,
tetracycline, oxytetracycline, chlortetracycline, demeclocycline, lymecycline, or pharmaceutically acceptable salts thereof.

31. A method for treating a mammal having a condition associated with bacteria that produce a calmodulin or a metalloproteinase exotoxin, or both, the method comprising administering to the mammal an effective, non-antibacterial amount of an antibacterial tetracycline, or a pharmaceutically acceptable salt thereof.

32. The method of claim 31, wherein the bacteria is selected from the group consisting of Bacillus anthracis, Clostridium perfringens, Bordetella pertussis, Bacteroides fragilis, or Pseudomonas aeruginosa.

33. The method of claim 31, wherein the bacteria is Bacillus anthracis.

34. The method of claim 31, wherein the bacteria produces a calmodulin exotoxin.

35. The method of claim 31, wherein the bacteria produces a metalloproteinase exotoxin.

36. The method of claim 31, wherein the bacteria produces both a calmodulin exotoxin and a metalloproteinase exotoxin.

37. The method according to claim 31, wherein the tetracycline is selected from the group consisting of terramycin, aureomycin, doxycycline, minocycline, tetracycline, oxytetracycline, chlortetracycline, demeclocycline, lymecycline, or pharmaceutically acceptable salts thereof.

38. The method according to claim 31, further comprising administering an antibiotic to the mammal.

39. The method according to claim 38, wherein the antibiotic is ciprofloxacin.

40. The method according to claim 38, wherein the antibiotic is doxycycline.
41. A method of protecting a mammal that has received or is scheduled to receive a vaccine against a bacteria that produces a calmodulin exotoxin, a metalloproteinase exotoxin, or both, the method comprising administering to the mammal an effective amount of a non-antibacterial tetracycline, or a pharmaceutically acceptable salt thereof.

42. The method of claim 41, wherein the bacteria is selected from the group consisting of *Bacillus anthracis*, *Clostridium perfringens*, *Bordetella pertussis*, *Bacteroides fragilis*, or *Pseudomonas aeruginosa*.

43. The method of claim 41, wherein the bacteria is *Bacillus anthracis*.

44. The method of claim 41, wherein the bacteria produces a calmodulin exotoxin.

45. The method of claim 41, wherein the bacteria produces a metalloproteinase exotoxin.

46. The method of claim 41, wherein the bacteria produces both a calmodulin exotoxin and a metalloproteinase exotoxin.

47. The method of claim 41, wherein the tetracycline is selected from the group consisting of CMT-1, CMT-2, CMT-4, CMT-6, CMT-7 or CMT-9, or pharmaceutically acceptable salts thereof.

48. The method of claim 41, wherein the tetracycline is selected from the group consisting of CMT-3, or its analogs, or pharmaceutically acceptable salts thereof.

49. The method according to claim 41, wherein the tetracycline is selected from the group consisting of CMT-8, or its analogs, or pharmaceutically acceptable salts thereof.

50. The method according to claim 41, wherein the tetracycline is selected from the group consisting of CMT-10, or its analogs, or pharmaceutically acceptable salts thereof.
51. The method according to claim 41, wherein the tetracycline is administered before the vaccine is administered.

52. The method according to claim 41, wherein the tetracycline is administered at the same time that the vaccine is administered.

53. The method according to claim 41, wherein the tetracycline is administered after the vaccine is administered.

54. A method of protecting a mammal that has received or is scheduled to receive a vaccine against a bacteria that produces a calmodulin exotoxin, a metalloproteinase exotoxin, or both, the method comprising administering to the mammal an effective, non-antibacterial amount of an antibacterial tetracycline, or a pharmaceutically acceptable salt thereof.

55. The method of claim 54, wherein the bacteria is selected from the group consisting of Bacillus anthracis, Clostridium perfringens, Bordetella pertussis, Bacteroides fragilis, or Pseudomonas aeruginosa.

56. The method of claim 54, wherein the bacteria is Bacillus anthracis.

57. The method of claim 54, wherein the bacteria produces a calmodulin exotoxin.

58. The method of claim 54, wherein the bacteria produces a metalloproteinase exotoxin.

59. The method of claim 54, wherein the bacteria produces both a calmodulin exotoxin and a metalloproteinase exotoxin.

60. The method according to claim 54, wherein the tetracycline is selected from the group consisting of terramycin, aureomycin, doxycycline, minocycline, tetracycline, oxytetracycline, chlortetracycline, demeclocycline, lymecycline, or pharmaceutically acceptable salts thereof.

61. The method according to claim 54, wherein the tetracycline is administered before the vaccine is administered.
62. The method according to claim 54, wherein the tetracycline is administered at the same time that the vaccine is administered.

63. The method according to claim 54, wherein the tetracycline is administered after the vaccine is administered.
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61N 87/18
US CL. : 514/159

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/159

Documentatation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EAST, WEST, DIALOG SF ALLESCIENCE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category*</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y</td>
<td>US 6,063,775 A (BERMAN) 16 May 2000, see entire document.</td>
<td>1-63</td>
</tr>
<tr>
<td>Y</td>
<td>US 6,277,061 B1 (GOLUB et al) 21 August 2001, see entire document.</td>
<td>1-63</td>
</tr>
<tr>
<td>Y</td>
<td>US 5,919,775 A (AMIN et al) 06 July 1999, see entire document.</td>
<td>1-63</td>
</tr>
<tr>
<td>Y, P</td>
<td>US 6,384,081 B2 (BERMAN) 07 May 2002, see entire document.</td>
<td>1-63</td>
</tr>
</tbody>
</table>

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:
  **A** document defining the general state of the art which is not considered to be of particular relevance
  **B** earlier document published on or after the international filing date
  **L** document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
  **O** document referring to an oral disclosure, use, exhibition or other means
  **P** document published prior to the international filing date but later than the priority date claimed
  **T** later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principles or theory underlying the invention
  **X** document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
  **Y** document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
  **Z** document member of the same patent family

Date of the actual completion of the international search

25 JUNE 2003

Date of mailing of the international search report

27 AUG 2003

Name and mailing address of the ISA/US Commissioner of Patents and Trademarks

Box PCT

Washington, D.C. 20231

Facsimile No. (703) 305-9230

Authorized Officer

JENNIFER GRASER

Telephone No. (703) 305-0196

Form PCT/ISA/910 (second sheet) (July 1998)